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ABSTRACT
Objective To identify valid and feasible quality
indicators for the primary care of osteoarthritis (OA).
Design Systematic review and narrative synthesis.
Data sources Electronic reference databases
(MEDLINE, EMBASE, CINAHL, HMIC, PsychINFO), quality
indicator repositories, subject experts.
Eligibility criteria Eligible articles referred to adults
with OA, focused on development or implementation of
quality indicators, and relevant to UK primary care. An
English language restriction was used. The date range
for the search was January 2000 to August 2013. The
majority of OA management guidance has been
published within this time frame.
Data extraction Relevant studies were quality
assessed using previous quality indicator methodology.
Two reviewers independently extracted data. Articles
were assessed through the Outcome Measures in
Rheumatology ﬁlter; indicators were mapped to
management guidance for OA in adults. A narrative
synthesis was used to combine the indicators within
themes.
Results 10 853 articles were identiﬁed from the
search; 32 were included in the review. Fifteen indicators
were considered valid and feasible for implementation in
primary care; these related to assessment non-
pharmacological and pharmacological management.
Another 10 indicators were considered less feasible, in
various aspects of assessment and management. A small
number of recommendations had no published
corresponding quality indicator, such as use of topical
non-steroidal anti-inﬂammatory drugs. No negative (‘do
not do’) indicators were identiﬁed.
Conclusions and implications of key ﬁndings
There are well-developed, feasible indicators of quality of
care for OA which could be implemented in primary
care. Their use would assist the audit and quality
improvement for this common and frequently disabling
condition.
BACKGROUND
Osteoarthritis (OA) is a common reason for con-
sultation with a general practitioner (GP): around
4% of the population aged 45 years and over will
consult a GP in a year with a diagnosis of OA.1
One working deﬁnition of OA is “persistent joint
pain that is worse with use [in people] age 45 years
old and over [who have] morning stiffness lasting
no more than half an hour” and does not require
radiography for diagnosis.2 There are evidence-
based interventions to reduce pain and disability in
adults with OA. Guidance on the care and manage-
ment of OA has been produced by the American
College of Rheumatology, the European League
Against Rheumatism, the Osteoarthritis Research
Society International, and the National Institute for
Health and Care Excellence (NICE).3–8 Although
management may vary by the site of OA, core
aspects of primary care management are generally
common across all sites.4–6 8 If these interventions
were routinely implemented by GPs, there would
be a signiﬁcant impact on population levels of pain
and disability attributable to OA.9 However, there
is evidence that such implementation is not occur-
ring.10–15
Routine audit and feedback on provided care is
needed to improve the quality of that care. Quality
indicators (hereafter ‘indicators’) are one suitable
tool.16 Such indicators are deﬁned as a “measurable
[element] of practice performance for which there
is evidence or consensus that it can be used to
assess the quality, and hence change in the quality,
of care provided”.17 Although reviews by
Hochberg18 and Strömbeck et al19 identiﬁed indi-
cators for measuring quality of care for OA, which
show promise for use in primary care, there has
been no systematic review and synthesis of the
development and implementation literature to iden-
tify the most promising and feasible set of primary
care OA indicators. Hunter et al20 argue cogently
for ‘further systematic development, implementa-
tion, and audit of quality measures.’ The objective
of this systematic review was to identify existing
indicators of core treatment for OA feasible for use
in primary care medical records and for routine
audit purposes through electronic data retrieval.
METHODS
We used the methodology for systematic reviews set
out by the Centre for Reviews and Dissemination.21
Review protocol
Available on request from the corresponding author.
Search strategy
A search strategy was developed to identify articles
concerning the development, testing or implementa-
tion of indicators of the quality of care for OA
applicable to adults in a primary medical care
setting.
The systematic search strategy was customised
for use in databases searchable through the UK
National Health Service (NHS) Evidence portal
(CINAHL, EMBASE, HMIC, MEDLINE and
PsychINFO). A range of OA terms were combined
with indicator terms. An English language restric-
tion was used. The date range for the search was
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January 2000 to August 2013. Further studies were identiﬁed
from other known repositories including the Agency for
Healthcare Research and Quality.22
The search strategy for use in MEDLINE via NHS Evidence
is shown in table 1.
Selection of eligible articles
The titles identiﬁed were entered in a bibliographical database
and duplicates removed. Titles were assessed for relevance by a
single reviewer ( JJE). The resulting abstracts were evaluated inde-
pendently by two reviewers ( JJE and MK). All those considered
relevant by one or both reviewers were entered into the next
round. The full texts of the resulting articles were obtained.
These were subject to dual independent review of their relevance
( JJE plus MK or KSD) and, if there was disagreement on inclu-
sion, by a third reviewer (KSD or MK). This process yielded a
ﬁnal set of articles for the data abstraction round.
Method of data extraction
Data extraction forms were designed using the assessment criteria
below. The extraction forms were piloted and reﬁned by three
reviewers. Data were independently extracted by two reviewers
( JJE plus MK or KSD). Differences in extraction were resolved
by discussion or by a third independent data extraction.
Assessment of indicators
The indicators were assessed for quality against criteria used previ-
ously, and based on the Outcome Measures in Rheumatology ﬁlter
(truth, discrimination, feasibility).23–28 The assessment criteria are
shown in the online supplementary text S1. Indicators were con-
sidered at the level of their development group (for the evidence
synthesis, consensus exercise and testing) and at the level of the
individual indicator (for discrimination and feasibility).
Narrative synthesis
The clinical reviewers (two experienced GPs—JJE and MK—
and an academic physiotherapist—KSD) together drafted a nar-
rative synthesis to collate the individual indicators, which was
then discussed and revised among all the authors. The indicators
were mapped to OA guidance.3–8 Indicator themes developed
from the best evidence and consensus method, and rated as feas-
ible for UK primary care, were transformed into a format suit-
able for implementation. This included a deﬁned numerator
(the number of patients receiving a particular element of care)
and denominator (those eligible for that element).
RESULTS
Selection of articles
Ten thousand eight hundred and ﬁfty-two unique articles were
identiﬁed. The ﬁnal inclusion set numbered 32. There were 10
groups of indicators in 14 development articles, and 18 imple-
mentation articles.
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) ﬂow chart setting out the review
process can be found in the online supplementary ﬁgure S2.
Excluded studies are listed in the online supplementary table S3.
Assessment of quality
The 10 groups of studies in which indicators for OA care had
been developed are listed in table 2. The following aspects of
quality assessment were common to all studies and are not
included in the table.
Although not every study explicitly declared there to be no
conﬂict of interest, the reviewers considered that no signiﬁcant
resulting bias of the results was likely.
No studies had an identiﬁed method of updating the indica-
tors in light of new evidence.
External validity and sensitivity to change had not been
demonstrated in any of the indicator development, testing or
implementation studies.
Reproducibility, at the level of the individual indicator, is
shown in table 3.
Of 10 indicator development study groups, ﬁve were based on
the Assessing Care of Vulnerable Elders (ACOVE) indicators.
Overall, the ACOVE series of indicators were found to most
closely fulﬁl the assessment criteria due to their robust evidence
collection and consensus development, and ﬁeld testing, and
update in ACOVE-3. The modiﬁcations to ACOVE-1 indicators
(for use the English Longitudinal Study of Aging,41 in nursing
homes42 and home-based primary care45) were minor, such as to
the target population or recommended care process time frames.
The degree to which modiﬁcations were subject to further empir-
ical study and consensus varied. We judged the modiﬁed indica-
tors to be compatible with the originals, although there was
variability regarding the indicators of use of oral non-steroidal
anti-inﬂammatories (NSAIDs) and gastroprotective agents, in
terms of the drugs recommended or the target population. The
RAND indicators were the earliest identiﬁed; they were based on
a literature review (not identiﬁed as systematic) and high-quality
consensus exercise. The developers of the Arthritis Foundation
indicators had undertaken a ‘comprehensive’ literature review,
and a high-quality consensus exercise. One example of imple-
mentation (of the non-pharmacological indicators) was found.
The remaining indicator sets used an evidence synthesis or con-
sensus exercise which was less rigorous, or not speciﬁed. Some
had no identiﬁed evidence of implementation (eg, Physician
Consortium for Performance Improvement (PCPI) indicators).
All identiﬁed articles used process-of-care measures as indica-
tors; one indicator set (European Musculoskeletal Conditions
Surveillance and Information Network; EUMUSC.net) also used
three outcome measures. We identiﬁed no papers in which
quality improvement over time had been investigated.
Table 1 MEDLINE search strategy
1 MEDLINE ((qualit* ADJ3 (outcome* OR indicat*))).ti,ab
2 MEDLINE QUALITY OF HEALTH CARE/
3 MEDLINE QUALITY ASSURANCE, HEALTH CARE/
4 MEDLINE BENCHMARKING/
5 MEDLINE CLINICAL AUDIT/
6 MEDLINE MEDICAL AUDIT/
7 MEDLINE FACILITY REGULATION AND CONTROL/
8 MEDLINE GUIDELINES AS TOPIC/
9 MEDLINE PRACTICE GUIDELINES AS TOPIC/
10 MEDLINE TOTAL QUALITY MANAGEMENT/
11 MEDLINE exp UTILIZATION REVIEW/
12 MEDLINE exp “OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)”/
13 MEDLINE QUALITY INDICATORS, HEALTH CARE/
14 MEDLINE 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11
OR 12 OR 13
15 MEDLINE osteoarthr*.ti,ab
16 MEDLINE exp OSTEOARTHRITIS/
17 MEDLINE 15 OR 16
18 MEDLINE 14 AND 17
19 MEDLINE 18 [Limit to: Publication Year 2000-Current and English
Language]
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Table 2 Indicator studies
Indicator set
Author and date
Truth
Target population
Proposed method
of measurement
Testing or
implementation Reliability FeasibilityEvidence synthesis Consensus method
RAND Quality of
Care Assessment
Tools (RAND QA)
Moore (2000)29
Literature review, not
specified to be systematic
RAND
Appropriateness
Method
Not specified Medical record
review
McGlynn et al30
Asch et al31
Tested in McGlynn et al30 and Asch
et al31 —in a 4% sample
reabstraction reliability was
substantial at 3 levels: presence of a
condition (к=0.83), indicator eligibility
(к=0.76) and indicator scoring
к=0.80)
McGlynn et al30 use a national sample
of US citizens in metropolitan areas,
using a telephone interview to collect
data with subsequent analysis of
medical records where consent was
given. Asch et al31 use the same data
as a comparator for data collected from
a random sample of veterans’ health
affairs clients and their records
ACOVE -1
MacLean
(2001)32 33
Systematic review supporting
indicators produced by a
content expert working with
a project member
knowledgeable about
systematic reviews and
quality indicator
development
Modified RAND/
UCLA
Appropriateness
Method
‘Vulnerable elders’—persons
≥65 years who are at
increased risk for death or
functional decline
Not specified Wenger et al34
Chodosh et al35
Higashi et al36 37
Ganz et al38
MacLean et al39
Østerås et al40
Tested in Wenger et al34—10%
sample reabstraction: overall error rate
was 1.6%; also in Chodosh
et al35—‘Inter-rater reliability of chart
abstraction for eligibility and scoring
of indicators was 95%.’; Higashi
et al36 37—10% reabstraction sample
showed 97% identical eligibility and
95% identical eligibility and quality
score; MacLean et al39—10%
reabstraction sample with к=0.85
(93% agreement); Østerås et al40
questionnaire-based test-retest
к=0.20–0.80, % exact agreement
from 62–90%
Wenger et al34 implemented the
indicators in community dwelling VEs
in the USA—medical record abstraction
by trained nurses supplemented for
some indicators by telephone
interview. Chodosh et al,35 Higashi
et al36 37 and MacLean et al39 used the
same population and methods. Ganz
et al used a similar population and
methodology at a different time point38
Østerås et al40 implemented some of
these indicators in a patient self-report
format
ACOVE-1 adapted
for the ELSA
Steel et al (2004)41
Transposition of previous
ACOVE work (referenced). 26
new indicators for the set
were suggested by the panel
Modified RAND/
UCLA
Appropriateness
Method
Older patients in the UK
≥65 years)
Interviews for the
ELSA
Steel et al,12 14
Broadbent et al,13
Østerås et al40
Tested in Steel et al12—(к=0.8, 95%
CI=0.7 to 0.9); Østerås et al40
questionnaire-based test-retest
к=0.20–0.80, % exact agreement
from 62–90%
Broadbent et al13 and Steel et al12
separately implemented indicators in
UK general practice, using medical
record review (computerised and paper
notes).
Østerås et al40 implemented some of
these indicators in a patient self-report
format
ACOVE-1 adapted
for NH
implementation
(ACOVE/NH)
Saliba et al
(2005)42
Previous referenced (ACOVE)
work, plus expert opinion
(for modification) and
additional indicator
development, methodology
not specified in detail
Modified Delphi;
subsequent overview
by ACOVE clinical
committee
Long-stay NH residents
≥65 years Exclusions for
advanced dementia or poor
prognosis
Not specified Cadogan et al43
Zingmond et al44
Tested in Cadogan et al43—к=0.65–
1.00 and percentage agreement 80–
100 where к could not be calculated
(numbers too low)
Cadogan et al43 implemented
indicators in 30 nursing homes in
California using medical record review.
Zingmond et al44 implemented using
Medicare and Medicaid eligibility and
claims data and a nursing home
minimum dataset
ACOVE-1 adapted
for the HPCQI
Smith et al
(2007)45
Based on ACOVE indicators,
plus some additional
(non-OA) indicators. ACOVE
work referenced; additional
expert opinion
Modified Delphi
techniques
Patients ≥60 years who are
homebound
Not specified No published
examples of testing
identified
No reliability testing identified No feasibility testing identified
ACOVE-3
ACOVE
investigators
(2007)46–48
A systematic review
supporting potential
indicators produced by a
content expert working with
Modified version of
the RAND/UCLA
Appropriateness
Method
Community-dwelling
individuals aged ≥65 years
who are at greater risk of
Medical records and/
or administrative
data, patient or
proxy interview
Østerås et al40 Østerås et al40 questionnaire-based
test-retest к=0.20–0.80, % exact
agreement from 62–90%
Østerås et al40 implemented some of
these indicators in a modified patient
self-report format
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Table 2 Continued
Indicator set
Author and date
Truth
Target population
Proposed method
of measurement
Testing or
implementation Reliability FeasibilityEvidence synthesis Consensus method
a project member
knowledgeable about
systematic reviews and
indicator development
death or functional decline
over a 2-year period
QIGP
Underwood
(2002)49
Various sources used
(Cochrane, DARE, Medline)
but not clear how the
evidence was assembled.
Cites meta-analyses,
systematic reviews,
randomised controlled trials
Not stated Not specified Not specified Kirk et al50
Steel et al12
Broadbent et al13
Østerås et al40
Tested for non-OA indicators in Kirk
et al50—as OA was not included in
this exercise, it is not known what
degree of reliability exists for these
indicators; Østerås et al40
questionnaire-based test-retest
к=0.20–0.80, % exact agreement
from 62–90%
Kirk et al50 implemented in 16 UK
general practices in two areas using
data from electronic and paper records.
Steel et al12 and Broadbent et al13
separately implemented the NSAID
indicator in UK general practice, using
medical record review (computerised
and paper notes).
Østerås et al40 implemented some of
these indicators in a modified patient
self-report format
Arthritis
Foundation
Arthritis
Foundation
200451 52
Comprehensive literature
search and expert opinion
Modified RAND/
UCLA
Appropriateness
Method
Patients with OA Not specified Li et al53 No reliability testing identified Li et al53 used a postal survey in
Canada (sampling frame from an
administrative database in British
Columbia) to assess
non-pharmacological indicators
PCPI (2006)54 PCPI website refers to a methodology committee but
no specific information in the indicator set to identify
how it was developed
All patients aged ≥21 years
with a diagnosis of OA
Medical record data
extraction (detailed
numerator and
denominator
information
provided)
No published
examples of testing
identified
No reliability testing identified No feasibility testing identified
EUMUSC.net
(2012)55
Developed from the EUMUSC.net standards of care
for OA and refined by researchers and patient
representatives
All adult patients with OA of
hand, hip or knee
Varies. Examples
include patient
record or survey.
Numerator and
denominator clearly
identified
No published
examples of testing
identified
No reliability testing identified No feasibility testing identified
ACOVE, Assessing Care of Vulnerable Elders; DARE, Database of Abstracts of Reviews of Effects; ELSA, English Longitudinal Study of Ageing; EUMUSC.net, European Musculoskeletal Conditions Surveillance and Information Network; HPCQI, Home-based
Primary Care Quality Initiative; NH, nursing home; NSAIDs, non-steroidal anti-inflammatories; OA, osteoarthritis, PCPI, Physician Consortium for Performance Improvement; QIGP, Quality Indicators for General Practice; UCLA, University of California, Los
Angeles; VE, vulnerable elder.
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Table 3 Narrative synthesis of exemplar indicators and their feasibility for use in primary care
Overarching theme (source) ‘Exemplar’ indicator Reproducibility (other sources of similar indicators) Implementation references and comment on feasibility
Holistic Assessment: Pain
(EULAR (all sites), NICE)
IF a VE has symptomatic OA of the knee or hip, THEN pain should be
assessed when new to a primary care or musculoskeletal disease practice
and annually… (ACOVE-3)46–48
RAND QA,29 ACOVE-1,32 33 and as adapted (ELSA,41
HPCQI45), Arthritis Foundation,51 52 PCPI,54 EUMUSC.
net55
12 13 30 31 34 35 38 40
Requires change in routine coding to improve capture of this
information
Holistic Assessment: Function
(ACR (hand), EULAR (all sites),
NICE )
IF a VE has symptomatic OA of the knee or hip, THEN functional status
should be assessed when new to a primary care or musculoskeletal disease
practice and annually…(ACOVE-3)46–48
RAND QA,29 ACOVE-1,32 33 and as adapted (ELSA,41
HPCQI45), Arthritis Foundation,51 52 PCPI54
12 13 30 31 35 38 40
Requires change in routine coding to improve capture of this
information
Education (EULAR (all sites),
NICE, OARSI)
IF a patient has had a diagnosis of symptomatic OA of the knee or hip for
>3 months, THEN education about the natural history, treatment, and
self-management of OA should have been given or recommended at least
once…(Arthritis Foundation)51 52
ACOVE-1 (2 variations—new and pre-existing
disease),32 33 and as adapted (ELSA41), EUMUSC.net55
12–14 34 38 40
Requires change in routine coding to improve capture of this
information
Exercise 1 and 2 (ACR (hip,
knee), EULAR (all sites), NICE,
OARSI
IF an ambulatory VE has symptomatic OA of the knee or hip for longer than
3 months and is able to exercise, THEN a directed or supervised muscle
strengthening or aerobic exercise program should be recommended and
activity reviewed annually…(ACOVE-3)46–48
Initial recommendation
RAND QA,29 ACOVE-1 (indicators for new and
pre-existing disease),32 33 and as adapted (ELSA,41
ACOVE/NH,42 HPCQI45), Arthritis Foundation,51 52
PCPI,54 EUMUSC.net55
Annual review
RAND QA,29 ACOVE-132 33
Initial recommendation
14 30 31 34 37 38 40 43 53
Annual review
53
Requires change in routine coding to improve capture of this
information
Weight loss 1 (ACR (hip,
knee), NICE, OARSI
IF a VE is obese (body mass index (BMI) ≥30 kg/m2), THEN he or she
should be advised annually to lose weight… (ACOVE-3)46–48
Arthritis Foundation51 52 No implementation studies identified for this indicator.
Should be captured from existing weight and health promotion
records
Weight loss 2 (ACR (hip,
knee), NICE, OARSI
IF a patient has symptomatic OA of the knee or hip and is overweight (as
defined by body mass index of ≥27 kg/m2), THEN the patient should be
advised to lose weight at least annually AND the benefit of weight loss on
the symptoms of OA should be explained to the patient…(Arthritis
Foundation)51 52
EUMUSC.net55 40 53
Consider a lower BMI threshold of 25 kg/m2 for consistency with
the usual definition of ‘overweight’. Should be captured from
existing weight and health promotion records.
Aids and devices 1 (ACR (hip,
knee), EULAR (hip, knee),
NICE, OARSI)
IF a VE has symptomatic OA of the hip or knee and has difficulty walking
that makes ADL difficult for longer than 3 months, THEN the need for
ambulatory assistive devices should be assessed…(ACOVE-3)46–48
Arthritis Foundation,51 52 EUMUSC.net55 40 53
Requires change in routine coding to improve capture of this
information
Aids and devices 2 (ACR
(hand), NICE)
IF a VE has symptomatic OA and has difficulty with non-ambulatory ADL,
THEN the need for ADL assistive devices should be assessed…
(ACOVE-3)46–48
Arthritis Foundation,51 52 EUMUSC.net55 40 53
Requires change in routine coding to improve capture of this
information
Paracetamol 1 (ACR (hip,
knee), EULAR (all sites), NICE,
OARSI)
IF a VE is started on pharmacological therapy to treat OA, THEN
acetaminophen should be tried first… (ACOVE-3)46–48
RAND QA,29 ACOVE-1,32 33 and as adapted (ELSA,41
ACOVE/NH,42 HPCQI45), QIGP,49 Arthritis
Foundation,51 52
12–14 30 31 34 36–38 40 43 50
Requires change in routine coding to capture over-the-counter
drug use
Paracetamol 2 (ACR (hip,
knee), EULAR (all sites), NICE,
OARSI)
IF oral pharmacological therapy for OA is changed from acetaminophen to a
different oral agent, THEN there should be evidence that the patient has
had a trial of maximum dose acetaminophen (suitable for age/
comorbidities)….(Arthritis Foundation)51 52
ACOVE-1,32 33 and as adapted (ELSA,41 ACOVE/NH,42
HPCQI45)
12 13 34 36 43
Requires change in routine coding to capture over-the-counter
drug use
Oral NSAIDs 1 (all guidance) If NSAIDs are considered, ibuprofen should be considered for first-line
treatment unless contraindicated or intolerant.* (QIGP)49
Modifications exist in implementation studies: Steel
et al,12 Broadbent et al13 to include use of COX-2
selective drugs
12 13 50
Requires change in routine coding to capture over-the-counter
drug use.
Oral NSAIDs 2 (all guidance) Percentage of patients aged 21 years and older with a diagnosis of OA on
prescribed or OTC NSAIDs who were assessed for GI and renal risk factors.
(PCPI)54
Two indicators from ACOVE-3 refer to risks from NSAIDs
and aspirin to be ‘discussed and documented’,46–48
EUMUSC.net55
12 13
Requires change in routine coding to capture over-the-counter
drug use
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Narrative synthesis
The indicators identiﬁed in the studies were grouped into
themes. A summary of exemplar indicators is shown in table 3.
The basis of the exemplar choice from the truth and feasibility
aspects of the evidence is shown (discrimination was not found
to be empirically supported). A list of indicators suitable for
routine implementation in primary care is shown in table 4.
Online supplementary table S4 lists indicators which do not cur-
rently provide sufﬁcient evidence or feasibility for implementa-
tion in primary care.
1. Holistic assessment
There were 28 occurrences of indicators related to holistic
assessment of patients.
Assessments of pain and function were relatively frequent.
The ACOVE-3 examples were rated most highly. Exemplar indi-
cators have been selected for these elements of care. Indicators
for joint examination and joint aspiration arose less frequently,
though were still the result of at least one high quality evidence
synthesis and consensus exercise, but had not successfully been
implemented.
2. Education and information
There were 18 occurrences of indicators for education in OA.
The Arthritis Foundation indicator was selected due to its cited
evidence synthesis and consensus method, and its consistency
with the previously implemented ACOVE-1 and recently pub-
lished EUMUSC.net indicators; no education indicator was
included in ACOVE-3. There was some variation in the time-
frames speciﬁed for education. It was not clear from most studies
implementing this indicator theme how the required level of
detail about type of education was obtained. For example, one
study asked the patient in a telephone interview “Has any doctor
or nurse ever talked to you about: (1) What your arthritis or joint
pain will be like as time goes on, or the natural history of arth-
ritis?, (2) How to keep your arthritis or joint pain from getting
worse?, (3) How your arthritis can be treated?”38; a criterion to
pass the indicator was at least one positive response. Evidence
from implementation studies suggests that the indicator as
worded is less feasible for implementation in primary care, requir-
ing either a more generic indicator or a series of speciﬁc patient
self-report indicators; we propose a more generic indicator.
The EUMUSC.net team includes an education indicator
aimed at clinicians, which we did not include as it is not a
patient-focused indicator.
3. Exercise and physiotherapy
There were 22 occurrences of indicators recommending or
prescribing exercise or physiotherapy. One targeted patients
with hand, hip and knee OA55; one self-report indicator imple-
mented also included patients with hand, hip or knee OA40; six
refer to exercise for patients with OA of the hip or knee; the
remainder specify those with knee OA. There were variations
between indicators on exercise, with some recommending that a
programme be ‘prescribed’, ‘recommended’ or ‘considered’.
Some referred to speciﬁc strengthening programmes, others to
general aerobic exercise, or physical therapy. For example, one
study used a record of prescription for lower extremity strength-
ening or ambulation with a Physical Therapist or Restorative
Nursing Assistant after OA diagnosis as a criterion43; others
used non-routine sources such as patient interview or unspeci-
ﬁed sources. Evidence from implementation studies suggests that
feasible indicators for primary care relate to the offer of exercise
advice or physiotherapy referral, and review of current
exercise activity. It would be feasible to separate two elements
of the ACOVE-3 indicator into an indicator for advice,Ta
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recommendation or prescription of exercise, and an indicator of
annual review of activity.
4. Weight management
There were eight occurrences of indicators regarding weight
loss in overweight patients, six for patients with OA and two for
primary prevention. There was some variation in the BMI inter-
vention threshold as well as in the type of advice or referral.
There were two implementation studies identiﬁed, of the
Arthritis Foundation indicator regarding weight management in
symptomatic OA, in which Li et al53 used entry to a weight-loss
programme or dietetics appointment as criteria for indicator
achievement and the weight loss advice self-report indicator in
Østerås et al40 A primary care indicator related to advice regard-
ing weight loss to reduce the risk of OA, or to improve symp-
toms in people with established OA would be feasible. A further
identiﬁed indicator, regarding referral to a weight-loss pro-
gramme if a person has been overweight for 3 years or more,
would be less feasible and desirable, due to greater difﬁculty
establishing the denominator population.
5. Assistive devices (ambulatory and other)
There were nine occurrences of indicators for assessment of
need for assistive devices. These covered assessment of need for
ambulatory and non-ambulatory assistive devices but there were
no speciﬁcally recommended interventions. Two examples of
implementation were found, of Arthritis Foundation indicators
(similar to and consistent with the ACOVE-3 indicators) by Li
et al,53 in which credit was given when a patient had seen a
physiotherapist or occupational therapist for ambulatory or non-
ambulatory devices respectively within the previous year, and
similar patient self-report indicators in Østerås et al.40 In line with
this, general indicators for referral or assessment for ambulatory or
assistive devices currently appear feasible in primary care.
6. Analgesics (paracetamol and oral NSAIDs)
There were 53 occurrences of indicators for use of analgesics
in OA. These covered topics such as assessment of current use
or consideration of analgesics; use of appropriate ﬁrst-line
analgesics; and risk assessment and communication. Preferred
indicators generally result from at least one high quality evi-
dence synthesis and consensus exercise, although the basis for
the NSAID risk assessment indicator from the PCPI is unclear54
(though consistent with a similar indicator from the ACOVE-1
group). Where available, the ACOVE-3 indicators were chosen.
Several indicators regarding use of paracetamol and NSAIDs are
considered feasible for use in primary care (see table 3).
Indicators regarding assessment of existing use and consider-
ation of additional treatment from the PCPI54 and an imple-
mented indicator regarding stronger analgesics (Østerås et al40)
were not selected due to an unspeciﬁed evidence base and con-
sensus approach; indicators regarding risk explanation were also
not selected due to difﬁculties implementing these in routine
data sources (without free text medical record analysis).
7. Gastroprotection
There were 13 occurrences of indicators for use of gastropro-
tective agents under certain conditions. However, there were
variations in the triggers for prescribing a gastroprotective
agent, and in the choice of agent to be used. The broadest
(PCPI) indicator54 cites a meta-analysis as having indicated that
use of gastrointestinal prophylaxis can be effective in reducing
the incidence of adverse events. This would be consistent with
the NICE recommendation that everyone over 45 years pre-
scribed a NSAID for OA should be coprescribed a proton pump
inhibitor.8 Where indicators have been implemented, they often
use past medical history or co-therapy with other agents (eg,
aspirin or warfarin) to determine the denominator group for
this indicator. The PCPI indicator is the most feasible, although
this has been narrowed to include only proton-pump inhibitor
gastroprotection in line with NICE guidance.
8. X-rays, injections, specialist assessment and joint replacement
There were 16 instances of indicators for referral to a special-
ist and use of X-rays when symptoms were not improving under
non-surgical care. As guidance for management of OA does not
recommend routine use of X-rays, and no examples of imple-
mentation of X-ray indicators was found, this indicator was not
considered feasible. A number of indicators referred to failure
Table 4 Proposed indicators for primary care implementation
Overarching theme Proposal for primary care implementation
Holistic Assessment: Pain % patients with a working diagnosis of OA with evidence of pain assessment within the previous 12 months
Holistic Assessment:
Function
% patients with a working diagnosis of OA with evidence of function assessment within the previous 12 months
Education % patients with a working diagnosis of OA with evidence of education or advice since diagnosis
Exercise 1 % patients with a working diagnosis of OA in the hip or knee with evidence of exercise advice or physiotherapy referral since diagnosis
Exercise 2 % patients with a working diagnosis of OA with evidence of an activity review within the previous 12 months
Weight loss 1 % patients with a BMI ≥30 kg/m2 who have a record of weight loss advice within the previous 12 months
Weight loss 2 % patients with a working diagnosis of OA with a BMI ≥25 kg/m2 who have a record of weight loss advice within the previous 12 months
Aids and devices 1 % patients with a working diagnosis of OA with evidence of functional impairment who are recorded as receiving a referral or assessment for
ambulatory assistive devices within the previous 12 months
Aids and devices 2 % patients with a working diagnosis of OA with evidence of functional impairment who are recorded as receiving a referral or assessment for
assistive devices within the previous 12 months
Paracetamol 1 % patients with a working diagnosis of OA with evidence of paracetamol as the first oral analgesic prescribed or advised since diagnosis
Paracetamol 2 % patients with a working diagnosis of OA taking oral analgesics or NSAIDs with evidence that a suitable maximal dose of paracetamol was
tried beforehand
Oral NSAIDs 1 % patients with a working diagnosis of OA with evidence of a standard NSAID or COX-2 inhibitor as the first oral NSAID prescribed or advised
since diagnosis
Oral NSAIDs 2 % patients with a working diagnosis of OA taking an oral NSAID with a documented risk assessment prior to first prescription
Gastroprotection % patients with a working diagnosis of OA taking an oral NSAID who are also prescribed a PPI or alternative gastroprotective agent
Specialist assessment % patients with a record of achievement of all other applicable indicators prior to specialist referral*
*That is, the other 14 indicators above, depending on applicability of weight and therapy indicators to individual patients.
BMI, body mass index; COX, cyclooxygenase; NSAIDs, non-steroidal anti-inflammatories; OA, Osteoarthritis; PPI, proton-pump inhibitor.
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of other therapies as a prerequisite for specialist referral but
‘failure’ was not consistently deﬁned. One study asked patients
if they had pain and functional impairment, and had been
offered a joint replacement or orthopaedic assessment.38
Another used a patient self-report to identify failure of conser-
vative treatment leading to referral.40 An indicator mandating
that all other indicators must have been recorded as appropri-
ately met prior to referral was considered to be feasible.
There was also one indicator implemented for the consider-
ation of steroid injections for acute symptomatic deterioration.40
This was not considered feasible for routine implementation in
primary care since acute deterioration is hard to identify from
the record and many injections take place in secondary care.
9. Outcome measure indicators
The EUMUSC.net project also identiﬁed three outcome
measures55:
▸ a 20% functional improvement within 3 months of a treat-
ment initiation or change
▸ a 20% reduction in pain within 3 months of a treatment ini-
tiation or change
▸ enablement of workforce participation for people of
working age.
These were considered less feasible for primary care due to
the complexity of accounting for comorbidities and case-mix.
DISCUSSION
Through a systematic review of OA indicators and a quality
appraisal of the indicator development and implementation, we
identiﬁed 15 indicators of the quality of primary care for OA
which could be implemented, beneﬁting patients, clinicians and
policy development.
While the conclusions of the published guidance diverge in
some aspects (particularly the use of Symptomatic Slow-Acting
Drugs in Osteo-Arthritis, and in some of the detail of oral
NSAID use and gastroprotection), the interventions recom-
mended by the different expert groups are broadly similar. The
selected indicators were broadly applicable across all the guid-
ance groups.
Within themes, there are differences between some of the
identiﬁed indicators. Indicators sometimes target differing popu-
lations (eg, OA of the knee or any OA), frequency or threshold
of assessment or intervention, type of treatment (eg, variation in
oral NSAID recommended, and type of gastroprotective agent).
These differences are not sufﬁciently major to cause difﬁculties
in the implementation of the underlying indicator theme.
There are some limitations in this review. There may be indi-
cators not captured by the search strategy (including any prior
to 2000, and non-English language indicators). Given the thor-
ough nature of the indicator development methodology for a
number of the indicator sets, it seems unlikely that any major
themes will have been omitted. In contrast with the assessment
of publications on randomised controlled trials (eg, the
approach taken by the Cochrane Collaboration), quality assess-
ment of indicators themselves is not a highly developed
methodology.56
We have selected indicators judged sufﬁciently robust and
feasible for use in routine practice. The use of indicators is
dependent upon systematic information capture. In the UK,
approximately 90% of prescriptions are obtained with no cost
to the patient, and over-the-counter analgesics are restricted in
quantity.57 Analgesics and NSAIDs indicators based on data
from computer-generated prescriptions are likely to be valid
with no change to recording practice. Other indicators would
require a change in coding practice (more detailed coded clinical
information). The indicators should be generally applicable to
countries with well-developed primary care systems and elec-
tronic medical records. The indicators would work best with
strategic implementation, for example by inclusion in the
Quality and Outcomes Framework of pay-for-performance in
UK primary care.58
While there are some domains with well-developed and valid
indicators, some elements do not have such indicators. For
example (1) Holistic assessment: all dimensions other than pain
and function, notably periodic review, a jointly formulated man-
agement plan and the effect of comorbidities; (2) Education and
self-management: the development of a self-management plan
and thermotherapy; (3) Non-pharmacological management:
manipulation and stretching, electrotherapy, bracing, joint sup-
ports, footwear and insoles; and (4) Pharmacological manage-
ment: topical NSAIDs, capsaicin and intra-articular injections.
In principle, some of these areas might be suitable for the devel-
opment of indicators.
We did not identify any negative (‘do not do’) indicators.
There are some areas of guidance from which one might use-
fully derive such indicators for use in primary care. For example,
the use of topical rubefacients, electroacupuncture, nutraceuticals,
or intra-articular hyaluronan injections, or referral for arthro-
scopic lavage for OA, based on the NICE guidance.8
We found no evidence of external validity (that implementa-
tion of indicators is associated with quality improvement).
Also, there is no evidence of indicators’ sensitivity to change,
so this must currently be assumed. The degree to which a
change in recording of the care processes actually reﬂects a
change in the quality of care delivered has not clearly been
identiﬁed. These areas warrant further investigation: an
increased use of patient-reported measures such as those used
by Østerås et al40 would help identify changes in process deliv-
ery and outcome.
We have identiﬁed a range of indicators for OA which have a
good evidence base, are consistent with international guidance,
and many of which have been implemented previously. As the
disease burden of OA is high, and much of it is presented clinic-
ally to GPs, incorporation of these indicators to routine primary
care practice is recommended.
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